|View printer-friendly version|
|Flex Pharma Educates Athletes about Breakthrough Discovery|
“The excitement around this scientific breakthrough is remarkable.
People in the endurance community and beyond are fascinated and
encouraged by the genius discovery from Nobel Prize-winner and company
Flex Pharma’s educational effort and awareness campaign around athletes
participating in high intensity sports has included participation in a
variety of endurance events, including IRONMAN Boulder, Leadville Trail
100 MTB and Leadville Trail 100 Run. The Company also will appear at the
IRONMAN World Championships presented by
The goal of Flex Pharma’s efforts is to take athletes beyond the traditional mindset that exercise-associated muscle cramps are caused by a problem with the muscle. Instead, the Company is highlighting the real culprit: the nerve. No matter what conditions impact muscle performance in the first place – heat, fatigue, dehydration, electrolyte loss, reduced blood flow – the cramping of a muscle is triggered by the excessive firing of motor neurons in the spinal cord. The muscle then bunches up and is unable to relax, resulting in loss of motor control and pain. Drawing on his Nobel Prize winning research, Dr. MacKinnon designed a sports beverage to stimulate sensory fibers and prevent the motor nerves from becoming hyper-excited, greatly reducing the risk of cramping. This novel mechanism of chemical neurostimulation is leading to a new category in nutrition: Neuromuscular Performance – a focus on creating and sustaining the right nervous system conditions in the body for optimal neuromuscular balance.
Individuals can follow the Company on Twitter (@flexpharma) and the Company's website (http://ir.flex-pharma.com/) to see the latest progress of the Company's pre-launch activities for its consumer product to prevent and treat exercise-associated muscle cramps.
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, our plans to develop and
commercialize our consumer products and the future availability of our
consumer products. These forward-looking statements are based on
management's expectations and assumptions as of the date of this press
release and are subject to numerous risks and uncertainties, which could
cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include,
without limitation: the status, timing, costs, results and
interpretation of our clinical studies; our ability to develop and
commercialize our consumer products; anticipated positioning and product
attributes of our consumer products; results of early clinical studies
as indicative of the results of future trials; and other factors
discussed in greater detail under the heading "Risk Factors" in our
Annual Report on Form 10-K for the year ended
Flex Pharma, Inc.